Gossamer Bio reacquires worldwide seralutinib rights from Chiesi ahead of NDA submission
Gossamer Bio plans a September seralutinib NDA after FDA talks as Chiesi rights, cash pressure and Phase 3 risk reshape the case.
Pharma & Biotech
Pharma & Biotech
What Chiesi’s $1.9bn KalVista deal reveals about the next phase of rare disease consolidation
Rare disease M&A is shifting from science risk to launch execution. Chiesi’s KalVista deal puts oral HAE therapy at the center.
Pharma & Biotech
How Chiesi Global Rare Diseases is positioning lomitapide for earlier lifecycle management in HoFH
CHMP backs paediatric lomitapide for HoFH. Read what this means for clinicians, regulators, and rare disease access across Europe.